SCHEDULE 13G/A: Wasatch Advisors LP Discloses 3.5% Stake in Castle Biosciences Inc.

Wasatch Advisors LP has filed an Amendment No. 6 to Schedule 13G, reporting beneficial ownership of 3.5% of Castle Biosciences Inc.'s common stock as of March 31, 2025.

Summary

• Wasatch Advisors LP, an investment adviser, reported beneficial ownership of 998,455 shares of Castle Biosciences Inc. common stock.
• This represents 3.5% of the total class of securities.
• Wasatch Advisors LP holds sole voting power and sole dispositive power over all 998,455 shares.
• The filing is an Amendment No. 6 to Schedule 13G, indicating previous filings by Wasatch Advisors LP regarding their stake in Castle Biosciences Inc.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a routine disclosure of beneficial ownership and does not inherently convey strong positive or negative sentiment regarding the issuer's performance. While a reduction in stake (implied by the 3.5% figure and Amendment No. 6) could be seen as slightly negative, the filing itself is a factual report.

Positives

• Continued institutional ownership by Wasatch Advisors LP, an investment adviser, in Castle Biosciences Inc.

Negatives

• The filing indicates a beneficial ownership of 3.5%, which is below the 5% threshold typically requiring an initial Schedule 13G filing, suggesting a potential reduction in Wasatch Advisors LP's stake from a previous higher level.

Future Outlook

NA

Management Comments

• Mike Yeates, CEO of Wasatch Advisors LP, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Castle Biosciences Inc.

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership, potentially signaling a reduction in a significant institutional stake.

Key Dates

Keywords

Castle Biosciences Inc, Wasatch Advisors LP, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake